5-bromo-8-methoxy-2,3-dihydrobenzo[b][1,4]dioxine | 190661-82-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: 5-bromo-8-methoxy-2,3-dihydrobenzo[b][1,4]dioxine
• 英文别名: 5-bromo-2,3-dihydro-8-methoxy-1,4-benzodioxin；5-bromo-2,3-dihydro-8-methoxy-1,4-benzodioxine；2,3-ethylenedioxy-4-methoxybromobenzene；5-Bromo-8-methoxy-1,4-benzodioxane；5-bromo-8-methoxy-2,3-dihydro-1,4-benzodioxine
• CAS: 190661-82-6
• 化学式: C₉H₉BrO₃
• 分子量: 245.073
• InChiKey: ZJNULBCPSOSUHJ-UHFFFAOYSA-N

物化性质

• 熔点：
  82-83 °C
• 沸点：
  296.4±40.0 °C(Predicted)
• 密度：
  1.545±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-bromo-8-methoxy-2,3-dihydrobenzo[b][1,4]dioxine 在 正丁基锂 、 硼酸三异丙酯 、 三氟甲磺酸 、 5% Pd(II)/C(eggshell) 、 potassium carbonate 、 三苯基膦 、 potassium hydroxide 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 乙醇 、 水 、 乙酸乙酯 、 2,3,4-三氟甲苯 为溶剂， 反应 8.0h， 生成 cis-4-cyano-4-(2,3-dihydro-8-methoxy-1,4-benzodioxin-5-yl)cyclohexanecarboxylic acid
  参考文献：
  名称：

  A Practical Synthesis of the PDE4 Inhibitor, KW-4490

  摘要：

  A practical and scalable synthesis of a PDE4 inhibitor KW-4490 (1) was developed. This improved synthesis features the construction of the 1-arylcyclohexene (9) by the Diels-Alder reaction followed by a newly established Bronsted acid-promoted hydrocyanation. Subsequent crystallization-induced dynamic resolution enabled the high-yield production of the desired cis-isomer (cis-8). The synthesis was achieved in seven steps in 37% overall yield.

  DOI：

  10.1021/op1001287
• 作为产物：
  描述：

  3-甲氧基儿茶酚 在 N-溴代丁二酰亚胺(NBS) 、 ammonium acetate 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 3.0h， 生成 5-bromo-8-methoxy-2,3-dihydrobenzo[b][1,4]dioxine
  参考文献：
  名称：

  GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS

  摘要：

  本公开提供了激活Wnt/β-连环蛋白信号通路并因此治疗或预防与信号转导相关的疾病的γ-二酮或其类似物；这些疾病包括骨质疏松症和骨关节病；骨发育不全、骨缺陷、骨折、牙周病、耳硬化症、伤口愈合、颅颌面缺陷、溶骨性骨病、创伤性脑损伤或脊柱损伤、与中枢神经系统分化和发育相关的脑萎缩/神经系统疾病，包括帕金森病、中风、缺血性脑疾病、癫痫、阿尔茨海默病、抑郁症、躁郁症、精神分裂症；耳部疾病如耳蜗毛细胞丧失；眼部疾病如老年性黄斑变性、糖尿病性黄斑水肿或视网膜色素变性以及与干细胞分化和生长相关的疾病，如脱发、造血相关疾病和组织再生相关疾病。

  公开号：

  US20140243349A1

文献信息

• Derivatives of benzofuran or benzodioxole
  申请人：Kyowa Hakko Kogyo Co., Ltd.

  公开号：US06514996B2

  公开（公告）日：2003-02-04

  An oxygen-containing heterocyclic compound represented by following Formula (I): wherein R1 and R2 independently represent hydrogen, lower alkyl, cyano, —(CH2)n—E1—CO—G1 (wherein E1 represents a bond, O, or NH; and G1 represents hydrogen, substituted or unsubstituted lower alkyl, OR6, or NR7R8; and n represents an integer of 0 to 4), or the like; R1 and R2 are combined to represent a saturated carbon ring together with a carbon atom adjacent thereto; or R2, and R11 or R13 described below are combined to form a single bond; R3 represents hydrogen, phenyl, or halogen; R4 represents hydroxy, lower alkoxy, or the like; A represents —C(R9)(R10)— or O; B represents O, NR11, —C(R12)(R13)—, or —C(R14)(R15)—C(R16)(R17)—; D represents (i) —C(R18)(R19)—X— (wherein X represents —C(R21)(R22)—, S, or NR23), (ii) —C(R19a)═Y— [Y represents —C(R24)—Z— (wherein Z represents CONH, CONHCH2, or a bond), or N], or (iii) a bond; and R5 represents aryl, an aromatic heterocyclic group, cycloalkyl, pyridine-N-oxide, cyano, or lower alkoxycarbonyl; or pharmaceutically acceptable salts thereof.

  根据您的要求，以下是该化学公式（I）的中文翻译： 一个含氧杂环化合物，由以下公式（I）表示：其中R1和R2独立代表氢、低级烷基、氰基、—(CH2)n—E1—CO—G1（其中E1代表一个键、O或NH；G1代表氢、取代或未取代的低级烷基、OR6或NR7R8；n代表0到4的整数），或类似物；R1和R2共同代表与相邻碳原子一起的饱和碳环；或者R2与下面描述的R11或R13结合形成一个单键；R3代表氢、苯基或卤素；R4代表羟基、低级烷氧基或类似物；A代表—C(R9)(R10)—或O；B代表O、NR11、—C(R12)(R13)—或—C(R14)(R15)—C(R16)(R17)—；D代表（i）—C(R18)(R19)—X—（其中X代表—C(R21)(R22)—、S或NR23）、（ii）—C(R19a)═Y— [Y代表—C(R24)—Z—（其中Z代表CONH、CONH 或一个键）或N]，或（iii）一个键；R5代表芳基、芳香杂环基、环烷基、吡啶-N-氧化物、氰基或低级烷氧基甲酸；或其药物可接受的盐。
• DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE
  申请人：——

  公开号：US20020128290A1

  公开（公告）日：2002-09-12

  An oxygen-containing heterocyclic compound represented by following Formula (I): 1 wherein R 1 and R 2 independently represent hydrogen, lower alkyl, cyano, —(CH 2 ) n —E 1 —CO—G 1 (wherein E 1 represents a bond, O, or NH; and G 1 represents hydrogen, substituted or unsubstituted lower alkyl, OR 6 , or NR 7 R 8 ; and n represents an integer of 0 to 4), or the like; R 1 and R 2 are combined to represent a saturated carbon ring together with a carbon atom adjacent thereto; or R 2 , and R 11 or R 13 described below are combined to form a single bond; R 3 represents hydrogen, phenyl, or halogen; R 4 represents hydroxy, lower alkoxy, or the like; A represents —C(R 9 )(R 10 )— or O; B represents O, NR 11 , —C(R 12 )(R 13 )—, or —C(R 14 )(R 15 )—C(R 16 )(R 17 )—; D represents (i) —C(R 18 )(R 19 )—X— (wherein X represents —C(R 21 )(R 22 )—, S, or NR 23 ), (ii) —C(R 19a )═Y— [Y represents —C(R 24 )—Z— (wherein Z represents CONH, CONHCH 2 , or a bond), or N], or (iii) a bond; and R 5 represents aryl, an aromatic heterocyclic group, cycloalkyl, pyridine-N-oxide, cyano, or lower alkoxycarbonyl; or pharmaceutically acceptable salts thereof.

  以下是由下式（I）表示的含氧杂环化合物： 其中R1和R2独立地表示氢、较低的烷基、氰基、—（CH2）n—E1—CO—G1（其中E1表示键、O或NH；G1表示氢、取代或未取代的较低烷基、OR6或NR7R8；n表示0到4的整数），或类似物；R1和R2结合表示与相邻碳原子一起形成饱和碳环；或R2，以及下文描述的R11或R13结合形成单键；R3表示氢、苯基或卤素；R4表示羟基、较低的烷氧基或类似物；A表示—C（R9）（R10）—或O；B表示O、NR11、—C（R12）（R13）—或—C（R14）（R15）—C（R16）（R17）—；D表示（i）—C（R18）（R19）—X—（其中X表示—C（R21）（R22）—、S或NR23）、（ii）—C（R19a）═Y—［Y表示—C（R24）—Z—（其中Z表示CONH、CONH 或键），或N］，或（iii）键；R5表示芳基、芳香杂环基、环烷基、吡啶-N-氧化物、氰基或较低烷氧羰基；或其药学上可接受的盐。
• Brønsted Acid-Promoted Hydrocyanation of Arylalkenes
  作者：Arata Yanagisawa、Tetsuya Nezu、Shin-ichiro Mohri

  DOI：10.1021/ol902244e

  日期：2009.11.19

  Nonactivated arylalkenes are effectively converted to tertiary benzylic nitriles in the presence of triflic acid and trimethylsilyl cyanide. The hydrocyanation reactions result in good to excellent yield when electron-donating groups are substituted on the benzene ring. The reaction conditions are mild and relatively safe, notably without need for handling hazardous hydrogen cyanide gas, providing

  在三氟甲磺酸和三甲基甲硅烷基氰化物的存在下，未活化的芳基烯烃可以有效地转化为叔苄基腈。当给电子基团被取代在苯环上时，氢氰化反应导致良好或极好的收率。反应条件温和且相对安全，特别是无需处理危险的氰化氢气体，从而可轻松轻松地获得叔苄基腈。该反应被用于制备PDE4抑制剂（3）以及一系列类似物。
• Oxygen-containing heterocyclic compounds
  申请人：——

  公开号：US20010056117A1

  公开（公告）日：2001-12-27

  The present invention relates to oxygen-containing heterocyclic compounds represented by the following formula (I): 1 wherein m represents an integer of 0 to 4; R 1 , R 2 , R 3 and R 4 independently represent a hydrogen atom, substituted or unsubstituted lower alkyl, etc.; R 5 represents substituted or unsubstituted lower alkoxy etc.; R 6 represents a hydrogen atom etc.; and Y represents the following formula (II): 2 wherein R 9 represents cyano etc., R 10 represents a hydrogen atom etc., R 1 represents carboxy etc., and R 2 represents a hydrogen atom etc.; and the like; or pharmaceutically acceptable salts thereof.

  本发明涉及氧含杂环化合物，其表示为以下式（I）：其中m代表0至4的整数；R1、R2、R3和R4独立地代表氢原子、取代或未取代的较低烷基等；R5代表取代或未取代的较低烷氧等；R6代表氢原子等；Y代表以下式（II）：其中R9代表氰基等，R10代表氢原子等，R1代表羧基等，R2代表氢原子等；以及类似的；或其药学上可接受的盐。
• Protease inhibitors
  申请人：SmithKline Beecham Corporation

  公开号：US20020173469A1

  公开（公告）日：2002-11-21

  The present invention provides compounds which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.

  本发明提供了一种抑制蛋白酶的化合物，包括卡他普星K，以及这些化合物的药物组合物和治疗骨量过度流失或软骨或基质降解疾病的方法，包括骨质疏松症；牙龈疾病，包括牙龈炎和牙周炎；关节炎，更具体地说是骨关节炎和类风湿性关节炎；帕吉特病；恶性高钙血症；以及代谢性骨病，通过向需要治疗的患者投与本发明的化合物来抑制骨量过度流失或过度软骨或基质降解。